NCT03174275 2026-02-23
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT07046221 2025-07-20
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT07019181 2025-06-13
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
The First Affiliated Hospital of Xiamen University
Phase 2 Not yet recruiting
NCT04821765 2025-05-30
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT06663059 2024-10-29
Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
Tang-Du Hospital
Phase 2 Recruiting
NCT05828381 2023-04-25
Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer
Fujian Medical University Union Hospital
Phase 2 Unknown
NCT05007145 2021-12-21
REVO
Fujian Cancer Hospital
Phase 2 Unknown
NCT04177875 2019-11-26
T+TP
Tongji Hospital
Phase 2 Unknown
NCT01372202 2019-01-25
J10130
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated